H.R. 1254

IN THE SENATE OF THE UNITED STATES

DECEMBER 8, 2011

Received; read twice and referred to the Committee on the Judiciary

AN ACT

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,

1 SECTION 1. SHORT TITLE.

_	~
2	This Act may be cited as the "Synthetic Drug Con-
3	trol Act of 2011".
4	SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I
5	OF THE CONTROLLED SUBSTANCES ACT.
6	(a) Cannabimimetic Agents.—Schedule I, as set
7	forth in section 202(c) of the Controlled Substances Act
8	(21 U.S.C. 812(c)) is amended by adding at the end the
9	following:
10	"(d)(1) Unless specifically exempted or unless listed
11	in another schedule, any material, compound, mixture, or
12	preparation which contains any quantity of
13	cannabimimetic agents, or which contains their salts, iso-
14	mers, and salts of isomers whenever the existence of such
15	salts, isomers, and salts of isomers is possible within the
16	specific chemical designation.
17	"(2) In paragraph (1):
18	"(A) The term 'cannabimimetic agents' means
19	any substance that is a cannabinoid receptor type 1
20	(CB1 receptor) agonist as demonstrated by binding
21	studies and functional assays within any of the fol-
22	lowing structural classes:
23	"(i) 2-(3-hydroxycyclohexyl)phenol with
24	substitution at the 5-position of the phenolic
25	ring by alkyl or alkenyl, whether or not sub-
26	stituted on the cyclohexyl ring to any extent.

26

1	"(ii) 3-(1-naphthoyl)indole or 3-(1-
2	naphthylmethane)indole by substitution at the
3	nitrogen atom of the indole ring, whether or not
4	further substituted on the indole ring to any ex-
5	tent, whether or not substituted on the naph-
6	thoyl or naphthyl ring to any extent.
7	"(iii) 3-(1-naphthoyl)pyrrole by substi-
8	tution at the nitrogen atom of the pyrrole ring
9	whether or not further substituted in the
10	pyrrole ring to any extent, whether or not sub-
11	stituted on the naphthoyl ring to any extent.
12	"(iv) 1-(1-naphthylmethylene)indene by
13	substitution of the 3-position of the indene ring
14	whether or not further substituted in the indene
15	ring to any extent, whether or not substituted
16	on the naphthyl ring to any extent.
17	"(v) 3-phenylacetylindole or 3-
18	benzoylindole by substitution at the nitrogen
19	atom of the indole ring, whether or not further
20	substituted in the indole ring to any extent
21	whether or not substituted on the phenyl ring
22	to any extent.
23	"(B) Such term includes—
24	"(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
25	hydroxycyclohexyl]-phenol (CP-47,497);

```
"(ii)
 1
                          5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-
 2
             hydroxycyclohexyl]-phenol (cannabicyclohexanol
 3
             or CP-47,497 C8-homolog);
 4
                  "(iii)
                               1-pentyl-3-(1-naphthoyl)indole
             (JWH-018 and AM678);
 5
                  "(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-
 6
             073);
 7
                  "(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-
 8
 9
             019);
                  "(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph-
10
11
             thoyl)indole (JWH-200);
                  "(vii)
12
                                                1-pentyl-3-(2-
13
             methoxyphenylacetyl)indole (JWH-250);
                  "(viii)
14
                                             1-pentyl-3-[1-(4-
15
             methoxynaphthoyl)]indole (JWH-081);
                  "(ix)
16
                                 1-pentyl-3-(4-methyl-1-naph-
17
             thoyl)indole (JWH-122);
18
                  "(x)
                                 1-pentyl-3-(4-chloro-1-naph-
             thoyl)indole (JWH-398);
19
20
                  "(xi)
                                 1-(5-fluoropentyl)-3-(1-naph-
21
             thoyl)indole (AM2201);
                  "(xii)
22
                                      1-(5-fluoropentyl)-3-(2-
23
             iodobenzoyl)indole (AM694);
                                 1-pentyl-3-[(4-methoxy)-ben-
24
                  "(xiii)
25
             zoyl]indole (SR-19 and RCS-4);
```

```
1
                  "(xiv)
                                      1-cyclohexylethyl-3-(2-
 2
             methoxyphenylacetyl)indole (SR-18 and RCS-
 3
             8); and
                 "(xv)
 4
                                              1-pentyl-3-(2-
             chlorophenylacetyl)indole (JWH-203).".
 5
 6
        (b) Other Drugs.—Schedule I of section 202(c) of
 7
   the Controlled Substances Act (21 U.S.C. 812(c)) is
 8
    amended in subsection (c) by adding at the end the fol-
 9
   lowing:
             "(18) 4-methylmethcathinone (Mephedrone).
10
             "(19) 3,4-methylenedioxypyrovalerone (MDPV).
11
             "(20)
                           3,4-methylenedioxymethcathinone
12
13
        (methylone).
             "(21) Naphthylpyrovalerone (naphyrone).
14
             "(22) 4-fluoromethcathinone (flephedrone).
15
             "(23)
                    4-methoxymethcathinone
16
                                               (methedrone;
17
        Bk-PMMA).
18
             "(24) Ethcathinone (N-Ethylcathinone).
19
             "(25)
                             3,4-methylenedioxyethcathinone
20
        (ethylone).
21
             "(26)
                                    Beta-keto-N-methyl-3,4-
22
        benzodioxyolybutanamine (butylone).
             "(27)
23
                                     N,N-dimethylcathinone
24
        (metamfepramone).
```

```
1
             "(28) Alpha-pyrrolidinopropiophenone (alpha-
 2
        PPP).
             "(29)
 3
                                           4-methoxy-alpha-
        pyrrolidinopropiophenone (MOPPP).
 4
             "(30)
                                         3,4-methylenedioxy-
 5
 6
        alphapyrrolidinopropiophenone (MDPPP).
                    Alpha-pyrrolidinovalerophenone (alpha-
 7
        PVP).
 8
 9
             "(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-
10
        6-amine) (MDAI).
             "(33) 3-fluoromethcathinone.
11
12
             "(34)
                         4'-Methyl-α-pyrrolidinobutiophenone
13
        (MPBP).
14
             "(35)
                                        2-(2,5-Dimethoxy-4-
        ethylphenyl)ethanamine (2C-E).
15
             "(36)
                                        2-(2,5-Dimethoxy-4-
16
17
        methylphenyl)ethanamine (2C–D).
             "(37)
18
                                            2-(4-Chloro-2,5-
19
        dimethoxyphenyl)ethanamine (2C-C).
             "(38)
20
                                              2-(4-Iodo-2,5-
21
        dimethoxyphenyl)ethanamine (2C-I).
             "(39)
                                        2-[4-(Ethylthio)-2,5-
22
        dimethoxyphenyl]ethanamine (2C-T-2).
23
             ((40)
                                    2-[4-(Isopropylthio)-2,5-
24
25
        dimethoxyphenyl]ethanamine (2C-T-4).
```

1	"(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-
2	H).
3	"(42) 2-(2,5-Dimethoxy-4-nitro-
4	phenyl)ethanamine (2C-N).
5	"(43) $2-(2,5-Dimethoxy-4-(n)-$
6	propylphenyl)ethanamine (2C-P).".
7	SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT
8	HAZARDS TO PUBLIC SAFETY EXPANSION.
9	Section 201(h)(2) of the Controlled Substances Act
10	(21 U.S.C. 811(h)(2)) is amended—
11	(1) by striking "one year" and inserting "2
12	years"; and
13	(2) by striking "six months" and inserting "1
14	year''.
	Passed the House of Representatives December 8,
	2011.
	Attest: KAREN L. HAAS,
	Clerk.